WASHINGTON (dpa-AFX) - Furiex Pharmaceuticals Inc. (FURX) confirmed that Takeda Pharmaceutical Company Limited has submitted to the U.S. Food and Drug Administration a new drug application or NDA for marketing approval of the fixed-dose combination alogliptin/metformin for type 2 diabetes.
Under Furiex's agreement with Takeda, this submission does not trigger a milestone payment to Furiex. Currently, Furiex receives royalty payments from Takeda for the sale of alogliptin products, trade names Nesina and Liovel, in Japan.
Copyright RTT News/dpa-AFX